Sanofi's strategy head to retire by month end, as company gears up for December strategic update

Natalie Grover

Reporter

While speculation that Sanofi is considering options for its consumer healthcare unit erupts ahead of a planned strategic update next month, it looks like …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi's strategy head to retire by month end, as company gears up for December strategic update

Natalie Grover

Reporter

Sign up to read this article for free.

Lilly drops body mass ranges from FDA label for weight loss drug

Coherus makes final, $483M pivot away from biosimilars

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Applied Therapeutics gets FDA warning letter over study of rejected rare disease drug

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Sanofi's strat­e­gy head to re­tire by month end, as com­pa­ny gears up for De­cem­ber strate­gic up­date

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Ap­plied Ther­a­peu­tics gets FDA warn­ing let­ter over study of re­ject­ed rare dis­ease drug

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Sanofi's strategy head to retire by month end, as company gears up for December strategic update

Lilly drops body mass ranges from FDA label for weight loss drug

Coherus makes final, $483M pivot away from biosimilars

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Applied Therapeutics gets FDA warning letter over study of rejected rare disease drug

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals